|
End-of-day quote
Egyptian Exchange
06/10/2026
|
5-day change | 1st Jan Change | ||
| 336.30 EGP | -0.80% |
|
+25.47% | +428.36% |
| 08-13 | GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 05-17 | GlaxoSmithKline Q1 consol net profit EGP 4.7 million | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 537M | - | - | - | - | - |
| 1,032B | |||||
| 614B | - | ||||
| 471B | |||||
| 350B | |||||
| 337B |
- Stock Market
- Stocks
- BIOC Stock
- Charts GlaxoSmithKline S.A.E
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
